| | Business Wire: Rhein Biotech and Corixa Enter Into License and... @ HighBeam Research (Site not responding. Last check: 2007-09-19) |
 | | Rhein Biotech N.V., the world's third largest manufacturer of hepatitis B vaccines, and Corixa Corporation (Nasdaq:CRXA), a developer of immunotherapeutics, today announced the signing of a license and supply agreement for the use of Corixa's synthetic adjuvant, RC-529, by Rhein Biotech. |
 | | Rhein Biotech has acquired from Corixa the co-exclusive worldwide commercial rights to Corixa's RC-529 synthetic adjuvant for use in Rhein Biotech's two-dose hepatitis B vaccine and therapeutic hepatitis B vaccine development program. |
 | | Rhein Biotech, in collaboration with Corixa, is developing a two-dose hepatitis B vaccine that includes Corixa's RC-529 adjuvant. |
| www.highbeam.com /library/doc0.asp?DOCID=1G1:84561293&refid=holomed_1 (942 words) |